Drug intelligence / Profile preview

China Medical Univ. ALK compound 14n

Lead developer
China Medical University
01

Targets

02

Identity

Originator
China Medical University
03

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

04

Companies

  • China Medical UniversityOriginator · Lead developer
05

Competitive landscape

Drugs on the same target
36

Most advanced

  1. alectinibApproved
  2. brigatinibApproved
  3. ceritinibApproved
  4. crizotinibApproved
  5. ensartinibApproved

Beyond the preview

Go deeper on China Medical Univ. ALK compound 14n.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Medical Univ. ALK compound 14n.

Work on China Medical Univ. ALK compound 14n? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call